scholarly journals Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

2021 ◽  
Author(s):  
Sean Wharton ◽  
Salvatore Calanna ◽  
Melanie Davies ◽  
Dror Dicker ◽  
Bryan Goldman ◽  
...  
Keyword(s):  
Weight Loss ◽  
Adverse Events ◽  
Gastrointestinal Tolerability ◽  
Gastrointestinal Adverse Events ◽  
The Relationship ◽  
Overweight Or Obesity

Abstract #611: The Impact of Gastrointestinal Adverse Events on Weight loss with Liraglutide 3.0 Mg as Adjunct to a Diet and Exercise Program

2015 ◽  
Vol 21 ◽  
pp. 118-119
Author(s):  
Michael Lean ◽  
Carel Le Roux ◽  
Ken Fujioka ◽  
Ian Caterson ◽  
Søren Lilleøre ◽  
...  
Keyword(s):  
Weight Loss ◽  
Adverse Events ◽  
Exercise Program ◽  
Diet And Exercise ◽  
Gastrointestinal Adverse Events ◽  
The Impact

scholarly journals Dairy Consumption and Cardiometabolic Risk Factors in Patients with Type 2 Diabetes and Overweight or Obesity during Intensive Multidisciplinary Weight Management: A Prospective Observational Study

Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1643
Author(s):  
Shaheen Tomah ◽  
Ahmed H. Eldib ◽  
Mhd Wael Tasabehji ◽  
Joanna Mitri ◽  
Veronica Salsberg ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Weight Management ◽  
Maintenance Phase ◽  
Intervention Phase ◽  
Dairy Consumption ◽  
Healthy Diets ◽  
The Relationship ◽  
Overweight Or Obesity

Dairy products are integral parts of healthy diets; however, their association with cardiometabolic (CM) health among patients with type 2 diabetes (T2D) undergoing weight management is debated. We examined the relationship between dairy consumption and CM biomarkers in 45 subjects with T2D and obesity (mean age 56 ± 9 yrs, 40% female) enrolled in a 12-week intensive multidisciplinary weight management (IMWM) program. After the IMWM program (intervention phase), subjects were followed for 12 weeks (maintenance phase). We stratified subjects based on initial average dairy consumption into infrequent (IFR), less-frequent (LFR), and frequent (FR) consumers. Outcomes were assessed at baseline, 12, and 24 weeks. There were no differences between tertiles at baseline except for higher total energy intake among FR compared with IFR. HbA1c changes showed no association with dairy consumption at 12 or 24 weeks. FR Females achieved greater weight loss at 12 weeks compared with IFR peers (−4.5 kg; 95%CI: −5.5, −3.5). There was a trend towards lower HDL-C with increasing dairy consumption during the intervention phase. In subjects with T2D and overweight or obesity, dairy consumption during weight management is not associated with HbA1c changes but with lower HDL-C and with higher magnitude of weight loss among females.

scholarly journals Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A63-A64
Author(s):  
Domenica M Rubino ◽  
Niclas Abrahamsson ◽  
Melanie Davies ◽  
Dan Hesse ◽  
Frank L Greenway ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Weight Loss ◽  
Body Weight ◽  
Waist Circumference ◽  
Adverse Events ◽  
Systolic Blood Pressure ◽  
Maintenance Dose ◽  
Treatment Policy ◽  
The Impact ◽  
Overweight Or Obesity

Abstract Background: In people with overweight or obesity, long-term maintenance of weight loss is challenging. Subcutaneous (s.c.) semaglutide, a glucagon-like peptide-1 analogue, has shown clinically-relevant weight loss in a phase 2 trial in people with obesity. STEP 4 investigated the impact of continued semaglutide 2.4 mg treatment, vs switching to placebo, on maintenance of weight loss in participants who reached 2.4 mg of semaglutide during a run-in period. Methods: This was a 68-week withdrawal trial (NCT03548987) in 902 subjects aged ≥18 years with body mass index (BMI) ≥30 kg/m2 (or BMI ≥27 kg/m2 with ≥1 weight-related comorbidity), without diabetes. Following a 20 week run-in period, 803 subjects who reached the maintenance dose of once-weekly (OW) s.c. semaglutide 2.4 mg were randomized 2:1 to continue treatment with semaglutide 2.4 mg or switch to placebo for 48 weeks, both as adjunct to lifestyle intervention. The primary endpoint was percentage change in body weight between randomization (week 20) and week 68. Confirmatory secondary endpoints included change in waist circumference and systolic blood pressure. Two estimands were defined: treatment policy and trial product; results are presented for the treatment policy estimand, unless stated otherwise. Results: Mean body weight (±SD) was 107.2 ±22.7 kg at week 0 and 96.1 ±22.6 kg at randomization (week 20; mean change -10.6%). Randomized participants were mostly female (79%) and white (84%); mean age was 46 years and mean BMI was 34.4 kg/m2. Between weeks 20–68, estimated mean body weight change was −7.9% vs +6.9% for semaglutide 2.4 mg vs placebo (estimated treatment difference [ETD]: −14.8%; 95% confidence interval [CI]: −16.0, −13.5; p<0.0001), and -8.8% vs 6.5%, respectively, for the trial product estimand (ETD: -15.3%; 95% CI: -16.5, -14.1; p<0.0001). For participants randomized to continue semaglutide, the estimated change in body weight from week 0–68 was -17.4% (-18.2% for trial product estimand). Continued semaglutide treatment (weeks 20–68) led to clinically-relevant improvements in waist circumference, systolic blood pressure, BMI, HbA1c, FPG, and lipids (total cholesterol, LDL, VLDL, and triglycerides) vs switching to placebo (p<0.0001 for all). During the run-in period, 5.3% of participants discontinued treatment due to adverse events; during the randomized period, 2.4% (semaglutide) and 2.2% (placebo) discontinued. Nausea, diarrhea and constipation (mostly transient and mild-to-moderate) were the most frequent adverse events with semaglutide. Conclusion: In adults with overweight or obesity, continued treatment after dose escalation with OW s.c. semaglutide 2.4 mg until week 68 led to clinically-relevant weight loss, while switching to placebo led to significant weight regain; these data underscore the chronicity and relapsing nature of obesity, and the need for continued treatment.

668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 668-P
Author(s):  
JURIS J. MEIER ◽  
RIKKE AGESEN ◽  
LARS BARDTRUM ◽  
ALICE Y. CHENG ◽  
SRIKANTH DEENADAYALAN ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Adverse Events ◽  
Body Weight Loss ◽  
Gastrointestinal Adverse Events

scholarly journals Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

2018 ◽  
Vol 20 (9) ◽  
pp. 2210-2219 ◽  
Author(s):  
Bo Ahrén ◽  
Stephen L. Atkin ◽  
Guillaume Charpentier ◽  
Mark L. Warren ◽  
John P. H. Wilding ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Adverse Events ◽  
Gastrointestinal Adverse Events ◽  
Baseline Bmi

Body Weight Loss With Oral Semaglutide is Independent of Gastrointestinal Adverse Events

2021 ◽  
Vol 45 (7) ◽  
pp. S14-S15
Author(s):  
Juris Meier ◽  
Rikke Agesen ◽  
Lars Bardtrum ◽  
Alice Cheng ◽  
Srikanth Deenadayalan ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Adverse Events ◽  
Body Weight Loss ◽  
Gastrointestinal Adverse Events

Pound Wise and Penny Foolish? Weight Loss and The Dynamics of Health Care Spending

2011 ◽  
Vol 14 (2) ◽  
Author(s):  
Thomas G Koch
Keyword(s):  
Weight Loss ◽  
Cost Savings ◽  
Cost Effective ◽  
Economic Consequences ◽  
Health Care Spending ◽  
Order Of Magnitude ◽  
Dynamic Measures ◽  
The Cost ◽  
The Impact ◽  
The Relationship

Current estimates of obesity costs ignore the impact of future weight loss and gain, and may either over or underestimate economic consequences of weight loss. In light of this, I construct static and dynamic measures of medical costs associated with body mass index (BMI), to be balanced against the cost of one-time interventions. This study finds that ignoring the implications of weight loss and gain over time overstates the medical-cost savings of such interventions by an order of magnitude. When the relationship between spending and age is allowed to vary, weight-loss attempts appear to be cost-effective starting and ending with middle age. Some interventions recently proven to decrease weight may also be cost-effective.

Sign in / Sign up

Export Citation Format

Share Document